Sleep deprivation and quality of life among uterine cancer survivors: systematic review.

INTRODUCTION: While cancer survival might be a relief from a near-death health condition, the after-recovery period also predisposes the survivors to deteriorated quality of life as well as sleep deprivation. Patients with cancer may experience post-traumatic stress disorder (PTSD) throughout the diagnostic process and even after diagnosis is completed, especially when facing the possibility of tumor recurrence. Survivors, in particular, are frequently in a condition of uncertainty due to the 15 to 20% chance of recurrence within 3 years of the main treatment. Despite the high rate of cancer survival, which is believed to be around 83%, assessing quality of life after a cancer diagnosis can help to improve such results. PURPOSE: This article aimed to describe the sleep patterns among uterine cancer survivors and verify psychological and physical factors affecting their general qualities of life. According to the qualitative study, uterine cancer survivors who receive treatment, whether pharmaceutical or therapeutic, have a higher quality of life than those who do not. METHOD: PRISMA reporting was used for this systematic review. Electronic databases that were searched include PubMed, Cochrane Trial Register, and ScienceDirect for studies evaluating the sleep deprivation and quality of life among uterine cancer survivors. Ten publications were chosen based on inclusion criteria that included uterine cancer survivors who had finished their treatments and addressed sleep quality or overall quality of life. RESULTS: The main finding of the systematic review is that 61% of uterine cancer survivors had poor sleep quality, and 81% have a decreased quality of life. CONCLUSION: According to the most recent research, uterine cancer survivors suffer from sleep deprivation, which leads to a lower quality of life. However, the same study reveals that uterine cancer survivors suffering with sleep loss use a variety of cognitive behavioral therapy to improve their quality of life. Maintaining a healthy diet, incorporating physical activity into daily routines, receiving cognitive behavior therapy, participating in relevant training programs, and obtaining frequent depression and sexual health screenings are just a few of the CBT mechanisms mentioned.

Iron is a ligand of SecA-like metal-binding domains in vivo.

The ATPase SecA is an essential component of the bacterial Sec machinery, which transports proteins across the cytoplasmic membrane. Most SecA proteins contain a long C-terminal tail (CTT). In Escherichia coli, the CTT contains a structurally flexible linker domain and a small metal-binding domain (MBD). The MBD coordinates zinc via a conserved cysteine-containing motif and binds to SecB and ribosomes. In this study, we screened a high-density transposon library for mutants that affect the susceptibility of E. coli to sodium azide, which inhibits SecA-mediated translocation. Results from sequencing this library suggested that mutations removing the CTT make E. coli less susceptible to sodium azide at subinhibitory concentrations. Copurification experiments suggested that the MBD binds to iron and that azide disrupts iron binding. Azide also disrupted binding of SecA to membranes. Two other E. coli proteins that contain SecA-like MBDs, YecA and YchJ, also copurified with iron, and NMR spectroscopy experiments indicated that YecA binds iron via its MBD. Competition experiments and equilibrium binding measurements indicated that the SecA MBD binds preferentially to iron and that a conserved serine is required for this specificity. Finally, structural modeling suggested a plausible model for the octahedral coordination of iron. Taken together, our results suggest that SecA-like MBDs likely bind to iron in vivo.

Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.

We synthesized a new series of 2-[(3-(4-sulfamoylphenethyl)-4(3H)-quinazolinon-2-yl)thio]anilide derivatives (2-16) and evaluated their cytotoxic activity against breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29), and acute myeloid leukemia (HL-60 and K562) cells. To reveal their selectivity toward cancer cells, the compounds were also tested against the human fibroblast cell line, MRC-5. Compounds 1-5 exhibited potent cytotoxic activity against the tested cell lines with IC50 values of 0.65-3.86, 0.68-4.60, 0.41-1.45, 0.42-4.07, and 3.77-25.55 µM, respectively compared to sorafenib, the standard drug (IC50 2.50, 2.50, and 3.14 µM against MCF-7, HT-29, and HL60 cells, respectively). Interestingly, compounds 1-5 displayed selectivity toward the cancer cell lines over MRC-5 (IC50 3.77-25.55 µM). These compounds also displayed potent inhibitory activity against EGFR and HER2 kinases (IC50 0.09-0.43 and 0.15-0.33 µM, respectively) compared to the standard drug, sorafenib (IC50 0.11 and 0.13 µM, respectively). Likewise, compounds 1, 4, and 5 showed strong inhibitory activity against VEGFR2 (IC50 0.34, 0.28 and 0.39 µM, respectively) compared to sorafenib (IC50 0.17 µM). We also employed molecular docking to identify the structural features required for the EGFR/HER2 inhibitory activity of the new series. Ultimately, compounds 1, 4, and 5 were demonstrated to be candidates for further preclinical investigations.

Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies.

A new series of 5,5-diphenylhydantoin derivatives containing benzylidene or isatin (4-19) was synthesized. Their anticancer activity against HeLa, a cervical cancer cell line, A549, a lung cancer cell line, and MDA-MB-231, a breast cancer cell line, was evaluated. Compounds 13, 16, 17 and 18 exhibited potent anticancer activity with average IC50 values against the tested cell lines of 109, 59, 81 and 113 µM, respectively. Compound 16 showed potent EGFR and VEGFR2 inhibitory activity with IC50 values of 6.17 and 0.09 µM, respectively. In addition, compound 16 induced caspase-dependent apoptosis and reactive oxygen species (ROS) production at 5 and 10 µM. Moreover, a molecular docking simulation was performed for compound 16 and sunitinib to predict the protein-ligand interactions with the active site of VEGFR2.